Alteogen

Pharma

Enhertu, Akeso, Fujifilm-Regeneron—Fierce Pharma Asia

Enhertu delivered a positive readout in first-line breast cancer. Akeso's ivonescimab bagged another phase 3 win. Fujifilm signed a 10-year deal with Regeneron.

Angus Liu Apr 25, 2025 8:45am

AstraZeneca-Alteogen, Taiho, WuXi—Fierce Pharma Asia

Mar 21, 2025 9:10am

AstraZeneca inks $1.35B deal for subcutaneous cancer drugs

Mar 17, 2025 10:55am

Daiichi enlists Alteogen for subcutaneous Enhertu in $300M deal

Nov 8, 2024 11:19am